Pascal Soriot - AstraZeneca

facebook_page
twitter_page

Last quote by Pascal Soriot

If you have a good early treatment then the incentive for screening is massive.feedback
share this quote
Sep 11 2017
We can learn a lot about a person if we know what types of things he or she talks about or comments on the most frequently. There are numerous topics with which Pascal Soriot is associated, including Crestor and BMS. Most recently, Pascal Soriot has been quoted saying: “The reason I didn't sign is that I felt there are so many areas that are still uncertain. How can we support something that we don't really understand fully?” in the article AstraZeneca CEO, worried by Brexit, not signing UK govt letter.
Automatically powered by Storyzy
Take our quote verification challenge and find out !

Pascal Soriot quotes

Jul 28 2017

Of course, we would have preferred to have everything positive. But ups and downs overall, we believe we can continue to secure the dividend.feedback

Jul 24 2017 - IMF

Nothing can break the momentum you have established, and certainly not rumours.feedback

Jun 05 2017

The data are important, they show there is a very significant clinical benefit, and they give us hope for the adjuvant study we have been running.feedback

Apr 27 2017

The pipeline continued to deliver in what we expect will be a pivotal year. The total revenue performance reflected the transitional impact of recent patent expiries, which is expected to recede in the second half of the year.feedback

Apr 27 2017

We're very committed to the UK. We are working very collaboratively with the government in this country to play our part in the development of a life sciences industry. What is, of course, necessary is that the government does implement policies that will be attracting investment, not only from large domestic companies like us and GSK (GlaxoSmithKline) but also from companies around the world.feedback

Feb 02 2017

It would be logical to assume that the EMA will have to stay with Europe and therefore the UK will have to have its own agency. That should be possible because it is in the interests of everybody and all the regulatory and scientific standards today are common. If you separate the two you could still decide to keep the same regulatory standards and as a result agree to recognize each others approvals.feedback

Nov 11 2016

The U.S. has always been a country that supports innovation ... and we hope it will remain the same. But we also believe we will continue to have to deal with price ressures.feedback

Nov 10 2016

The performance in the third quarter was in line with our expectations, reflecting the transitional impact from the first full quarter of generic competition to Crestor in the U.S.feedback

Oct 07 2016

Suddenly, this trial news opens quite some opportunities for us, in both monotherapy and combination therapy.feedback

Oct 07 2016

We're coming from a place where everybody thought we were behind and we have a very good chance to play in both the monotherapy and combination segments.feedback

Oct 07 2016

Being first is definitely important.feedback

Oct 07 2016

It gives us a chance to do what BMS was trying to do, but do it in a less risky manner, by expanding the population from the 50 percent PD-L1 cut-off to a bit broader.feedback

No quotes...
More Pascal Soriot quotes
|< <
> >|

Quotes by Pascal Soriot

<
>
Quote Verifier
verify-icon
Check if the quote you read on social networks is authentic
facebook_page
twitter_page
This webpage has been created by a robot: errors and absent quotes cannot be totally avoided
 
Feedback×

Quote :

Mistake :

Comments :